Why Is Regeneron Pharmaceuticals, Inc. Bucking the Downtrend?
Last week saw a widespread downturn among biotech stocks. Regeneron Pharmaceuticals, however, was able to move modestly higher. Why?
5 Biotechs With Prostate Cancer Treatments Worth Watching
Prostate cancer is now the second leading cause of cancer-specific deaths among men in the United States. Here are five biotechs aiming to meet this challenge with a diversity of promising new therapies.
Will Biogen Idec Inc. Rule Biotech in 2014?
Off the laurels of its success with Tecfidera, Biogen hits another success with its latest FDA approval.
Is Your Portfolio Exposed to Corruption Risk?
Shareholders in multinational companies like Siemens and Wal-Mart have been hit hard by unexpected corruption charges. Consider whether you might be at risk, too.
1 Piece of News That Could Move Exelixis
Data from Exelixis (EXEL) phase 3 trial of Cometriq in prostate cancer should be released soon. If results are positive, Johnson & Johnson (JNJ), Medivation (MDVN), and Bayer (BAYRY) may face a new competitor.
3 Upcoming FDA Meetings You Should be Watching
With three FDA panel meetings to close out the month investors should have their eyes on these three companies.
Can These Companies Bounce Back from Disappointing Sales?
Promising blood thinner Eliquis hasn't quite lived up to the hype surrounding it in its early life. Can Pfizer and Bristol-Myers Squibb turn things around?
Why Pfizer Investors Should Watch Quark This Summer
A read out on a mid stage trial this summer may offer clues as to whether Pfizer (PFE) may someday have a competitor to Novartis (NVS) and Regeneron (REGN)
5 Big Pharma Stocks With the Strongest Ties to Emerging Markets
Since emerging markets usually offer the best growth prospects, these five big pharmas have devoted the biggest percentage of their sales to these regions.